EMA/709116/2022

European Medicines Agency decision

P/0402/2022

of 9 September 2022

on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine / tenofovir alafenamide (Descovy), (EMEA-001577-PIP02-14-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

European Medicines Agency decision

P/0402/2022

of 9 September 2022

on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine / tenofovir alafenamide (Descovy), (EMEA-001577-PIP02-14-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0032/2015 issued on 16 February 2015, the decision P/0024/2017 issued on 31 January 2017, the decision P/0171/2018 issued on 15 June 2018 and the decision P/0034/2021 issued on 27 January 2021,

Having regard to the application submitted by Gilead Sciences International Ltd. on 25 April 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 22 July 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for emtricitabine / tenofovir alafenamide (Descovy), age-appropriate oral formulation, film-coated tablet, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Gilead Sciences International Ltd., Flowers Building, Granta Park, Great Abington, CB21 6GT - Cambridge, United Kingdom.

EMA/PDCO/244476/2022 Corr
Amsterdam, 22 July 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001577-PIP02-14-M05

Scope of the application

Active substance(s):

Emtricitabine / tenofovir alafenamide

Invented name:

Descovy

Condition(s):

Treatment of human immunodeficiency virus (HIV-1) infection

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Age-appropriate oral formulation

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Gilead Sciences International Ltd.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Gilead Sciences International Ltd. submitted to the European Medicines Agency on 25 April 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0032/2015 issued on 16 February 2015, the decision P/0024/2017 issued on 31 January 2017, the decision P/0171/2018 issued on 15 June 2018 and the decision P/0034/2021 issued on 27 January 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 23 May 2022.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of human immunodeficiency virus (HIV-1) infection

The waiver applies to:

- the paediatric population from birth to less than 4 weeks of age;
- age-appropriate oral formulation, film-coated tablet, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of human immunodeficiency virus (HIV-1) infection

2.1.1. Indication(s) targeted by the PIP

Treatment of human immunodeficiency virus (HIV-1) infected paediatric patients in combination with other antiretroviral (ARV) agents

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 weeks to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Age-appropriate oral formulation

Film-coated tablet

2.1.4. Measures

Area	**Description**
Quality-related studies	**Study 1** Development of film-coated tablets for use in children weighing 14 to less than 25 kg **Study 2** Development of an age-appropriate oral formulation for use in children from 4 weeks and weighing ≥ 3 kg to less than 14 kg of weight, and in children from 14 to less than 25 kg of weight unable to swallow tablets
Non-clinical studies	Not applicable
Clinical studies	**Study 8**

	Open-label, multicentre, two-part, single-arm trial to evaluate the pharmacokinetics (PK), safety, tolerability, and antiviral activity of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single tablet regimen (E/C/F/TAF STR) in HIV-1 infected antiretroviral treatment-naive, adolescents (from 12 to less than 18 years of age) and virologically suppressed children (from 6 to less than 12 years of age) (GS-US-292-0106) *This study is the same as study 2 of the elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide procedure EMEA-001460-PIP01-13-M01 and subsequent modifications thereof* **Study 3** Open-label, uncontrolled trial to evaluate pharmacokinetics (PK), safety, tolerability and efficacy of emtricitabine/tenofovir alafenamide (F/TAF) fixed-dose combination (FDC) in children from 2 years to less than 18 years of age with HIV-1 infection, who are virologically suppressed on an antiretroviral (ARV) regimen or treatment-naïve (GS-US-311-1269) **Study 4** deleted in EMEA-001577-PIP02-14-M03 **Study 5** deleted in EMEA-001577-PIP02-14-M04 ***Study 9*** Open-label trial to evaluate pharmacokinetics, safety and efficacy of cobicistat-boosted protease inhibitors and once-daily emtricitabine/tenofovir alafenamide each administered as part of combined ARV regimen in HIV-1 infected children aged from 4 weeks to less than 18 years of age (GS-US-216-0128) *This is the same study as Study 4 of the cobicistat PIP EMEA-000969-PIP01-10 and subsequent modifications thereof*
Extrapolation, modelling and simulation studies	**Study 6** Population PK model of the use of F/TAF FDC in combination with boosted or unboosted third antiretroviral agents in children from 4 weeks to less than 18 years of age **Study 7** Extrapolation study to support the use of the F/TAF FDC with boosted or unboosted third antiretroviral agents in children from 4 weeks to less than 18 years
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of human immunodeficiency virus (HIV-1) infection

   Authorised indication(s):

   - Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use